ENTR-601-45 not checked
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Duchenne Muscular Dystrophy (DMD) (2 trials)
- Main trialPhase 2
- “This is a study of investigational medicines ENTR-601-44 and ENTR-601-45 designed to evaluate the long-term safety and tolerability of study drugs in participants with Duchenne muscular dystrophy (DMD). The investigational medicines are currently being investigated in multiple ascending dose parent studies. After participants complete their respective parent study, there is a need to understand the effects of long-term administration of ENTR-601-44 and ENTR-601-45. Participants enrolling in this study will begin this long-term extension (LTE) study at the dose level they received upon…”In the company’s words, NCT07682129 on ClinicalTrials.gov
Other drugs for Duchenne Muscular Dystrophy (DMD)
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- GivinostatItalfarmaco · Phase 3
- SGT-003Solid Biosciences Inc. · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
- DeramiocelCapricor Inc. · Phase 3
- DS-5141bDaiichi Sankyo · Phase 2
Coming up2
- 1 Mar 2029Phase 1/2 trial completes · ClinicalTrials.gov
- Mar 2032Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Mar 2032 | Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) | |
| Phase 1/2Recruiting | 1 Mar 2029 | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026